First-line treatment efficacy of anti-EGFR versus anti-VEGF antibodies in BRAFV600E-mutated metastatic colorectal cancer according to primary tumor sidedness: A pooled analysis of seven clinical trials performed in the first-line treatment of mCRC (German AIO Study Group)
European Journal of Cancer · 2026-01 · 232 · 116105
DOI: 10.1016/j.ejca.2025.116105 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift European Journal of Cancer, 2026-01. Verfasst von Lena Weiss und 19 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine III and Comprehensive Cancer Center (CCC Munich LMU), University Hospital, LMU Munich, Munich, Germany. Electronic address: Le…. Hauptthemen laut MEDLINE: Colorectal Neoplasms, Neoplasm Metastasis, Vascular Endothelial Growth Factor A, ErbB Receptors. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medicine III and Comprehensive Cancer Center (CCC Munich LMU), University Hospital, LMU Munich, Munich, Germany. Electronic address: Lena.Weiss@med.uni-muenchen.de.
- Department of Hematology, Oncology and Cancer Immunology (CCM), Charité-Universitätsmedizin Berlin, Freie Universität Berlin, Humboldt-Universität zu Berlin and Berlin Institute of Health, Berlin, Germany; DKTK Heidelbe…
- Department of Hematology, Oncology and Cancer Immunology (CCM), Charité-Universitätsmedizin Berlin, Freie Universität Berlin, Humboldt-Universität zu Berlin and Berlin Institute of Health, Berlin, Germany.
- MVZ Gesundheitszentrum St. Marien GmbH, Amberg, Germany.
- Department of Hematology, Oncology and Palliative Care, St. Josef-Hospital, Ruhr-University Bochum, Bochum, Germany.
- Onkologie Ravensburg, Ravensburg, Germany.
Zitieren
APA
Weiss, L., Stintzing, S., Modest, D. P., Stahler, A., von Weikersthal, L. F., Reinacher-Schick, A., Decker, T., Probst, V., Heinrich, K., Schwaner, I., Kaiser, F., Pihusch, R., Fuchs, M., Held, S., Alig, A., Gruenberger, B., Prager, G. W., Tougeron, D., Taieb, J., & Heinemann, V. (2026). First-line treatment efficacy of anti-EGFR versus anti-VEGF antibodies in BRAFV600E-mutated metastatic colorectal cancer according to primary tumor sidedness: A pooled analysis of seven clinical trials performed in the first-line treatment of mCRC (German AIO Study Group). European Journal of Cancer, 232, 116105. https://doi.org/10.1016/j.ejca.2025.116105
Vancouver
Weiss L, Stintzing S, Modest DP, Stahler A, von Weikersthal LF, Reinacher-Schick A, et al. First-line treatment efficacy of anti-EGFR versus anti-VEGF antibodies in BRAFV600E-mutated metastatic colorectal cancer according to primary tumor sidedness: A pooled analysis of seven clinical trials performed in the first-line treatment of mCRC (German AIO Study Group). European Journal of Cancer. 2026;232:116105. doi:10.1016/j.ejca.2025.116105
BibTeX
@article{Weiss2026,
author = {Weiss, Lena and Stintzing, Sebastian and Modest, Dominik Paul and Stahler, Arndt and von Weikersthal, Ludwig Fischer and Reinacher-Schick, Anke and Decker, Thomas and Probst, Victoria and Heinrich, Kathrin and Schwaner, Ingo and Kaiser, Florian and Pihusch, Rudolf and Fuchs, Martin and Held, Swantje and Alig, Annabel and Gruenberger, Birgit and Prager, Gerald Werner and Tougeron, David and Taieb, Julien and Heinemann, Volker},
title = {First-line treatment efficacy of anti-EGFR versus anti-VEGF antibodies in BRAFV600E-mutated metastatic colorectal cancer according to primary tumor sidedness: A pooled analysis of seven clinical trials performed in the first-line treatment of mCRC (German AIO Study Group)},
journal = {European Journal of Cancer},
year = {2026},
volume = {232},
pages = {116105},
doi = {10.1016/j.ejca.2025.116105}
}
EUVIMED